# Lakeland Industries Inc: overview LAKE · Nasdaq · CIK 798081 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 31 Pages: [Overview](/companies/lake.md) · [Financials](/companies/lake/financials.md) · [Filings](/companies/lake/filings.md) · [Insiders](/companies/lake/insiders.md) Latest reported revenue: [$50.1m](/filings/0001193125-26-386590.md) for Q2 FY2027, three months to 2026-07-31, from the 10-Q filed Sep 9, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-386590). ## Last eight quarters | Line item | Unit | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [45.8](/filings/0001193125-25-312871.md) | [46.6 d](/filings/0001193125-26-159176.md) | [46.7](/filings/0001193125-26-264001.md) | [52.5](/filings/0001193125-26-386590.md) | [47.6](/filings/0001193125-25-312871.md) | [45.8 d](/filings/0001193125-26-159176.md) | [47.4](/filings/0001193125-26-264001.md) | [50.1](/filings/0001193125-26-386590.md) | | Gross margin | % | [40.6%](/filings/0001193125-25-312871.md) | [40.1% d](/filings/0001193125-26-159176.md) | [33.5%](/filings/0001193125-26-264001.md) | [35.8%](/filings/0001193125-26-386590.md) | [29.7%](/filings/0001193125-25-312871.md) | [32.2% d](/filings/0001193125-26-159176.md) | [31.4%](/filings/0001193125-26-264001.md) | [37.0%](/filings/0001193125-26-386590.md) | | Operating margin | % | [1.8%](/filings/0001193125-25-312871.md) | [(22.9%) d](/filings/0001193125-26-159176.md) | [(9.9%)](/filings/0001193125-26-264001.md) | [(7.7%)](/filings/0001193125-26-386590.md) | [(3.4%)](/filings/0001193125-25-312871.md) | [(11.4%) d](/filings/0001193125-26-159176.md) | [4.8%](/filings/0001193125-26-264001.md) | [(6.7%)](/filings/0001193125-26-386590.md) | | Net margin | % | [0.2%](/filings/0001193125-25-312871.md) | [(39.5%) d](/filings/0001193125-26-159176.md) | [(8.4%)](/filings/0001193125-26-386590.md) | [1.5%](/filings/0001193125-26-386590.md) | [(33.5%)](/filings/0001193125-25-312871.md) | [(13.6%) d](/filings/0001193125-26-159176.md) | [0.8%](/filings/0001193125-26-386590.md) | [(9.8%)](/filings/0001193125-26-386590.md) | | Diluted EPS | $ per share | [0.01](/filings/0001193125-25-312871.md) | not reported | [(0.41)](/filings/0001193125-26-264001.md) | [0.08](/filings/0001193125-26-386590.md) | [(1.64)](/filings/0001193125-25-312871.md) | not reported | [0.04](/filings/0001193125-26-264001.md) | [(0.50)](/filings/0001193125-26-386590.md) | | Free cash flow | $m | [(9.1) d](/filings/0001193125-25-312871.md) | [(3.4) d](/filings/0001193125-26-159176.md) | [(6.1)](/filings/0001193125-26-264001.md) | [(5.7) d](/filings/0001193125-26-386590.md) | [(9.3) d](/filings/0001193125-25-312871.md) | [1.7 d](/filings/0001193125-26-159176.md) | [4.4](/filings/0001193125-26-264001.md) | [(0.4) d](/filings/0001193125-26-386590.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2023 (2023-04-30) | FY2024 (2024-01-31) | FY2024 (2024-04-30) | FY2025 (2025-01-31) | FY2026 (2026-01-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.0](/filings/0001654954-23-004860.md) | [125](/filings/0001654954-25-004352.md) | [6.3](/filings/0001654954-23-004860.md) | [167](/filings/0001193125-26-159176.md) | [193](/filings/0001193125-26-159176.md) | | Gross margin | % | not reported | [41.1%](/filings/0001654954-25-004352.md) | not reported | [41.1%](/filings/0001193125-26-159176.md) | [32.9%](/filings/0001193125-26-159176.md) | | Operating margin | % | not reported | [4.8%](/filings/0001654954-25-004352.md) | not reported | [(5.5%)](/filings/0001193125-26-159176.md) | [(8.1%)](/filings/0001193125-26-159176.md) | | Net margin | % | not reported | [4.4%](/filings/0001654954-25-004352.md) | not reported | [(10.8%)](/filings/0001193125-26-159176.md) | [(13.1%)](/filings/0001193125-26-159176.md) | | Diluted EPS | $ per share | not reported | [0.72](/filings/0001654954-25-004352.md) | not reported | [(2.43)](/filings/0001193125-26-159176.md) | [(2.63)](/filings/0001193125-26-159176.md) | | Free cash flow | $m | not reported | [8.8](/filings/0001654954-25-004352.md) | not reported | [(17.4)](/filings/0001193125-26-159176.md) | [(16.4)](/filings/0001193125-26-159176.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit. - Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues; Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Revenue: us-gaap:Revenues; Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lake/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $14.1m | 1,319,086 | | Added +105,664 | | [Private Capital Management, LLC](/funds/1588456.md) | 2026-06-30 | $13.4m | 1,249,274 | | Reduced −258,949 | | [Pacific Ridge Capital Partners, LLC](/funds/1591546.md) | 2026-06-30 | $10.4m | 975,881 | | Added +46,900 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.2m | 393,129 | | Added +1,829 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $3.4m | 320,235 | | Reduced −8,909 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $2.9m | 268,285 | | Reduced −615 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $2.5m | 234,575 | | New +234,575 | | [Peapod Lane Capital LLC](/funds/2050979.md) | 2026-06-30 | $2.2m | 207,657 | | Added +79,539 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.0m | 182,802 | | Reduced −17,600 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.7m | 158,276 | | Reduced −398,161 | ## Recent filings [All 981 filings](/companies/lake/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-09 | 17:00 ET | [10-Q](/filings/0001193125-26-386590.md) | Quarterly report, period 2026-07-31 | 0001193125-26-386590 | | 2026-09-09 | 16:15 ET | [8-K](/filings/0001193125-26-386460.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-386460 | | 2026-06-18 | 16:20 ET | [8-K](/filings/0001193125-26-275911.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-275911 | | 2026-06-09 | 17:05 ET | [10-Q](/filings/0001193125-26-264001.md) | Quarterly report, period 2026-04-30 | 0001193125-26-264001 | | 2026-06-09 | 16:20 ET | [8-K](/filings/0001193125-26-263790.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-263790 | | 2026-05-07 | 16:03 ET | [DEF 14A](/filings/0000798081-26-000008.md) | Proxy statement, period 2026-06-16 | 0000798081-26-000008 | | 2026-04-21 | 17:28 ET | [10-K/A](/filings/0001193125-26-167279.md) | Annual report, amended, period 2026-01-31 | 0001193125-26-167279 | | 2026-04-16 | 16:45 ET | [10-K](/filings/0001193125-26-159176.md) | Annual report, period 2026-01-31 | 0001193125-26-159176 | | 2026-04-16 | 16:12 ET | [8-K](/filings/0001193125-26-159019.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-159019 | | 2026-03-30 | 08:36 ET | [8-K](/filings/0001193125-26-130491.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-130491 | ## Latest annual report [Form 10-K for the fiscal year ended Jan 31, 2026](/filings/0001193125-26-159176.md), filed Apr 16, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 798081 - Tickers: LAKE - Exchange: Nasdaq - SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.